StockGlow

PMV Pharmaceuticals, Inc. (PMVP)

Develops cancer drugs that fix broken p53 proteins in tumor cells.

$1.11-0.06%Healthcare
Compare PMVP with
StockGlow Score
23
Leaning Bearish
BearishBullish
1 year ago-20.7%

The outlook

PMVP is trading near its 52-week lows, well below both its 50- and 200-day moving averages, reflecting downward momentum. Analyst coverage shows a notably bullish average target about 260% above the current price, though the overall sentiment leans bearish at 23/100. The stock sits at the lower end of its 52-week range.

What’s behind the score

Price trendBelow its 50- & 200-day averages
52-week range10% of the way from its 52-week low to high
Price targetAvg target +260% vs current price

Analyst price target

~12-month · 4 analysts
$4.00average target+260.4% vs now
Now $1.11
Low $3.00High $5.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$59.2M
52-wk high
$1.88
52-wk low
$1.02
50-day avg
$1.22
200-day avg
$1.29
Trailing P/E
—

Similar stocks

PRLDPrelude Therapeutics Incorporated$4.30+10.54%ALXOALX Oncology Holdings Inc.$1.99-1.49%NKTXNkarta, Inc.$2.26-0.22%CCCCC4 Therapeutics, Inc.$3.52-1.95%ZNTLZentalis Pharmaceuticals, Inc.$4.53+0.44%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy